A HOSPITAL BASED STUDY: EPIDEMOLOGY AND PRESENTATION OF BENIGN PROSTATIC HYPERPLASIA
DOI:
https://doi.org/10.63666/ejsmr.1694-9013.2.I.2025.32Keywords:
Benign Prostatic Hyperplasia (BPH), Epidemiology, HospitalAbstract
Introduction: Benign prostatic hyperplasia, is one of the most prevalent disorders that affects male population in every part of the world. The incidence of BPH has increased over the past ten years due to an increase in modifiable risk factors, such as obesity and metabolic disease whereas aging is found to be the most common non modifiable risk factor for BPH.
Objective: The main objective of this study is to find the epidemiology and presentation of BPH cases with their treatment modilaty at hospital in Jalalabad.
Method and methodology: Its a retrospective study of 75 patients who were diagnosed with BPH and came for different types of intervention and treatment in City Hospital in the year 2022 at Jalalabad, Kyrgystan.
Results: The age distribution in this study shows the maximum respondents age group of 60-75 years with 66.6%. According to our study 61.33% of the respondents are having a BMI value more than 25. More than 70% respondents were following up case of BPH who were under medication. Most of respondents had multiple disease whereas most common associate disease are hypertension (22.6%) and diabetes mellitus (13.3%). On symptoms analysis, Frequency of micturation was most common presentation found (86.66 %). Among the respondent, 41.33% were suffering from moderate symptoms and 38.66% were suffering from severe symptoms. 56.66% of the respondents have prostate size between 40-90cc and most common complication associate was acute retention of urine (9.33%). Most of respondent (49.4%) were currently on medical management and 34.6% of respondents underwent surgical management. patient who patient who underwent surgery, 80.76 % underwent TURP followed by open prostatectomy.
Conclusion: The study shows that the increasing age is the risk factor for the prevalence of BPH. In the future, this condition will undoubtedly become even more common and a significant burden for all health care systems due to a shifting demographic profile and an aging population in practically every society. Exercise and nutrition recommendations are crucial strategies in addition to medication and surgery, as they empower patients to take charge of their own health.
References
1. Dwitawira Wibowo N, Rizky Hidayat M. The Impact Of Benign Prostate Hyperplasia Treatment Modalities On The Incidence And Progression Of Urethral Stricture : A Comprehensive Systematic Review. Journal Of Advanced Research In Medical And Health Science (Issn 2208-2425) [Internet]. 2024 Apr 29 [Cited 2024 Dec 11];10(4):124–32.
2. Levi A Deters, MD; Chief Editor: Edward David Kim, MD, FACS [Updated: Mar 22, 2023], available from :https://emedicine.medscape.com/article/437359-overview#a5
3. National Cancer Institute. Prostate-Specific Antigen (PSA) Test. Cancer.gov. [Internet]. Available from: https://www.cancer.gov
4. Haile ES, Sotimehin AE, Gill BC. Medical management of benign prostatic hyperplasia. Cleveland Clinic journal of medicine. 2024 Mar 1;91(3):163–70.
5. Ye Z, Wang J, Xiao Y, Luo J, Xu L, Chen Z. Global burden of benign prostatic hyperplasia: results from the global burden of disease study 2019. BMC Urology. 2024 Sep 5;24(1).
6. GBD 2019 BPH collaborators, Omid Dadras. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019
7. Kurmanbekov N.K., Keneev R.N., Satybaldyev E.Е.,Stambekova K.N., Kylychbekov M.B. Analysis of the incidence of prostate diseases and their early detection based on the results of a scientific project for the study of the male population in the Kyrgyz Republic. Health care of Kyrgyzstan 2022, No. 3, pp. 140-147.
8. Lim K. B. (2017). Epidemiology of clinical benign prostatic hyperplasia. Asian journal of urology, 4(3), 148–151. https://doi.org/10.1016/j.ajur.2017.06.004
9. Awedew AF, Han H, Abbasi B, Abbasi-Kangevari M, Ahmed MB, Almidani O, et al. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Healthy Longevity [Internet]. 2022 Nov 1;3(11):e754–76.
10. Wang W, Guo Y, Zhang D, Tian Y, Zhang X. The prevalence of benign prostatic hyperplasia in mainland China: evidence from epidemiological surveys. Scientific Reports. 2015 Aug 26;5(1).
11. Batai K, Phung M, Bell R, Aye Aye Lwin, Hynes K, Price E, et al. Correlation between body mass index and prostate volume in benign prostatic hyperplasia patients undergoing holmium enucleation of the prostate surgery. BMC Urology. 2021 Jun 10;21(1).
12. Fowke JH, Koyama T, Fadare O, Clark PE. Does Inflammation Mediate the Obesity and BPH Relationship? An Epidemiologic Analysis of Body Composition and Inflammatory Markers in Blood, Urine, and Prostate Tissue, and the Relationship with Prostate Enlargement and Lower Urinary Tract Symptoms. Hurst R, editor. PLOS ONE. 2016 Jun 23;11(6):e0156918.
13. Kim JM, Song PH, Kim HT, Moon KH. Effect of Obesity on Prostate-Specific Antigen, Prostate Volume, and International Prostate Symptom Score in Patients with Benign Prostatic Hyperplasia. Korean Journal of Urology. 2011;52(6):401.
14. Nandy PR, Saha S. Association between components of metabolic syndrome and prostatic enlargement: An Indian perspective. Medical Journal Armed Forces India. 2016 Oct;72(4):350–5.
15. Shih HJ, Huang CJ, Lin JA, Kao MC, Fan YC, Tsai PS. Hyperlipidemia is associated with an increased risk of clinical benign prostatic hyperplasia. The Prostate. 2017 Nov 9;78(2):113–20.
16. Egan KB, Burnett AL, McVary KT, Ni X, Suh M, Wong DG, et al. The Co-occurring Syndrome—Coexisting Erectile Dysfunction and Benign Prostatic Hyperplasia and Their Clinical Correlates in Aging Men: Results From the National Health and Nutrition Examination Survey. Urology [Internet]. 2015 Jun 17 [cited 2025 Jan 28];86(3):570–80
17. Irene Pascual Mathey L (2022) Benign Prostatic Hyperplasia: Epidemiology, Pathophysiology, and Clinical Manifestations. Molecular Mechanisms in Cancer. IntechOpen. Available at: http://dx.doi.org/10.5772/intechopen.104823.
18. Mobley D, Feibus A, Baum N. Benign prostatic hyperplasia and urinary symptoms: Evaluation and treatment. Postgraduate Medicine. 2015 Mar 30;127(3):301–7.
19. Obiesie AE, A M E Nwofor, Oranusi CK, Mbonu OO. Correlation between Prostate Volume Measured by Ultrasound and Symptoms Severity Score in Patients with Benign Prostatic Hypertrophy in Southeastern Nigeria. Nigerian Journal of Clinical Practice [Internet]. 2022 Aug 1 [cited 2025 Jan 28];25(8):1279–86.
20. Speakman M, Cheng X. Management of the complications of BPH/BOO. Indian Journal of Urology. 2014;30(2):208.
21. Lokeshwar SD, Harper BT, Webb E, Jordan A, Dykes TA, Neal Jr DE, et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Translational Andrology and Urology [Internet]. 2019 Oct;8(5):529–39
22. Bishr M, Boehm K, Trudeau V, Tian Z, Dell’Oglio P, Schiffmann J, et al. Medical management of benign prostatic hyperplasia: Results from a population-based study. Canadian Urological Association journal = Journal de l’Association des urologues du Canada [Internet]. 2016;10(1-2):55–9
23. Ng M, Leslie SW, Baradhi KM. Benign Prostatic Hyperplasia. [Updated 2024 Jan 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK558920/
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Eurasian Journal of Scientific and Multidisciplinary Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
